Mogrify

Biotech & Life Sciences · Cambridge, United Kingdom · Founded 2016

Transforming the development of life saving cell therapies via the licence of proprietary cell conversions tailored to any therapeutic application MoreLess

Mogrify operates in the biotechnology sector, focusing on the development of ex vivo cell therapies and pioneering in vivo reprogramming therapies. The company has developed a proprietary platform that leverages transcriptomic and epigenetic data to identify optimal combinations of transcription factors for converting any cell type into another. This technology is aimed at addressing diseases with high unmet clinical needs by enabling scalable and efficient cell conversions. Mogrify serves pharmaceutical companies, research institutions, and healthcare providers, offering solutions that enhance the development and maintenance of cell therapies. The business model is based on licensing its technology, forming strategic partnerships, and executing royalty-bearing deals. Revenue is generated through upfront payments, milestone payments, and royalties from commercialized therapies.

Keywords: biotechnology, cell therapy, reprogramming, transcriptomic data, epigenetic data, transcription factors, scalable solutions, pharmaceutical partnerships, healthcare innovation, royalty deals.

Valuation $0–100M

Revenue <$1M

Headcount <100

Total funding $10–50M

Unlock exact values

Company overview

Mogrify company information

The essential company record, classifications and operating signals in one place.

Status: Operational
Founded: 2016
Headquarters: Cambridge, United Kingdom
Employees: 11
Open positions: None listed
Dealroom signal: 61.6

Website ↗LinkedIn ↗X ↗

client focusb2btechnologyBig Datasub industryBioTechnologybusiness modelManufacturingindustryHealthsectorBiotechnologysectorPrecision MedicinesectorSynthetic BiologysectorSpinoutsectorBiotech and PharmasectorAI Drug DiscoverysectorTechbiosectorTechbio Drug DiscoverysectorLongevity

Valuation & funding

Mogrify funding history

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Oct 2023	$10M	$85M	Astellas Venture · Ahren Innovation Capital · Jonathan Milner · Parkwalk Advisors	↗
SERIES AEquity / VC	Sep 2021	$0	—	Undisclosed	—
SERIES A✓Equity / VC	May 2021	$17M	$68M	24Haymarket · Dr Darrin M Disley OBE · Parkwalk Advisors · Jonathan Milner	—
EARLY VC✓Equity / VC	Jan 2020	$1.1M	$4.4M	Undisclosed	—
SERIES A✓Equity / VC	Oct 2019	$16M	$64M	University of Bristol Enterprise Fund · 24Haymarket · Parkwalk Advisors · Ahren Innovation Capital	—
SEED✓Equity / VC	Feb 2019			24Haymarket · Ahren Innovation Capital	—
SPINOUT✓Other financing	Jan 2019			University of Bristol	—
SPINOUT✓Other financing	Feb 2016			Monash University	—

Showing 8 recorded eventsUnlock the complete deal history →

Financials

Revenue, earnings and profit over time

Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.

Year	Revenue	Growth	EBITDA	Margin	Profit	Margin
2026	$405K	0%	−$12M	-3066.1%	−$3.5M	-860.2%
2025	$405K	0%	−$12M	-3066.1%	−$3.5M	-860.2%
2024	$405K	0%	−$12M	-3066.1%	−$7.8M	-1915.6%
2023	$405K	0%	−$12M	-3066.1%
2022	$405K	-12.5%	−$12M	-3066.1%
2021	$463K	—	−$13M	-2830.4%
2020	—	—	−$19K	—

Company filings, research estimates and Dealroom dataOpen the full financial model →

Growth signals

Mogrify website traffic

Latest recorded traffic for Mogrify is 300 monthly website visits, down 61.5% over the last three months. Mogrify's team declined 21.4% over the past year.

Latest monthly visits300 3-month web change-61.5% 1-year team growth-21.4%

Monthly website visits100 observations · Mar 2018–Jul 2026

Hover or focus a point to see its exact monthly valueCompare with peers →

Comparisons

Mogrify compared with similar companies

Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
BIbit.bioDeveloping a scalable technology platform capable of producing consistent batches of every human cell	Cambridge, United Kingdom	Operational	155	$225M	$200M
CECellVoyantAn AI-first biotechnology company with a mission to create novel stem cell-based therapies for chronic diseases	Bristol, United Kingdom	Operational
NANanoSyrinxA cutting-edge synthetic biology company creating the next generation of targeted drug delivery systems to address challenges in the biologic delivery sector	Coventry, United Kingdom	Operational
NTNucleome TherapeuticsDecoding the dark matter of the human genome to discover first-in-class precision medicine	Oxford, United Kingdom	Operational
FAFluidic AnalyticsDevelops microfluidic tools for protein analysis in research and clinical applications	Cambridge, United Kingdom	Acquired
SBSphere BioEnabling rapid screening and characterisation of single cells	Cambridge, United Kingdom	Operational
SYSynthaceEngineering biology for health, food, energy and manufacturing.	London, United Kingdom	Operational
GLGround Truth LabsGround Truth Labs AI platform measures intricate spatial biomarkers in routine histopathology slides, aiding drug development, de-risking trials, and enhancing clinical diagnosis	London, United Kingdom	Operational

Showing 8 of the closest matchesCompare every metric →

Talent graph

Mogrify's talent

Book a demo to see the people

Team profiled 15 named & role-tagged

Founders /100 quality score

Key operators 5 quality /100

Potential founders likely future founders

Startup mafia alumni-founded startups

Talent movements in · out past 12 months

Source: Dealroom Talent Intelligence.

Investors

10 investors on Mogrify's cap table

Sourced from Dealroom's funding and investor records.

Seed 2 investors entered at this stage

Ahren Innovation Capital

24Haymarket

Series A 5 investors entered at this stage

University of Bristol Enterprise Fund

Parkwalk Advisors

Dr Darrin M Disley OBE

Jonathan Milner

Astellas Venture

Other known 3 additional known investors

Monash University

University of Bristol

D+V Nachfolge

Global footprint

Where Mogrify has talent and traffic

Workforce by country

4 countries with
team presence

🇬🇧 United Kingdom75%

🇺🇸 United States8.3%

🇦🇺 Australia8.3%

🇨🇭 Switzerland8.3%

4 countries shown

In the news

Latest news about Mogrify

Recent press, funding announcements, and product moves mentioning Mogrify — open to read from the original sources.

See all news

Market sentiment

What the market is saying about Mogrify

An AI-synthesized read of the highest-engagement posts about Mogrify on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Mogrify’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Request a free trial

Takes under a minute. Already use Dealroom? Log in.